Endobronchial Valves for Endoscopic Lung Volume Reduction: Best Practice Recommendations from Expert Panel on Endoscopic Lung Volume Reduction.
Dirk-Jan Slebos, Pallav L Shah, Felix J F Herth...
https://pubmed.ncbi.nlm.nih.gov/27992862/Actively Recruiting
Led by Beth Israel Deaconess Medical Center · Updated on 2026-04-13
20
Participants Needed
1
Research Sites
N/A
Total Duration
Researchers are conducting a pilot randomized controlled trial to study a new lung fissure completion strategy combined with endobronchial valve EBV placement in patients with severe COPD or emphysema who have incomplete lung fissures less than 95% completion. The goal is to see if completing the lung fissures surgically can reduce collateral ventilation between lung lobes and improve outcomes after EBV placement. The study will enroll about 20 patients and focus on complications, lung function tests, and symptom questionnaires over a 3-month follow-up. Participants will be randomly assigned to either receive the experimental intervention, which includes robotic or video-assisted thoracic surgery VATS to complete the lung fissure followed by EBV placement, or to a medical management group receiving usual care. The surgical procedure involves stapling the incomplete fissures under general anesthesia, followed by assessment of collateral ventilation and valve placement during the same or a closely timed procedure. Patients in the medical management group may choose to cross over to the intervention after 3 months. During the study, participants will undergo bronchoscopy, pulmonary function tests, quality of life questionnaires Saint George Respiratory Questionnaire, COPD Assessment Test, and dyspnea assessment modified Medical Research Council scale. Follow-up visits at 14 days and 3 months will collect clinical data, CT scans, and lung function results. Safety and adverse events will be monitored throughout, with a total participation period of about 3 months plus possible crossover treatment.
CONDITIONS
Combined Zephyr Valve System With Inter-lobar Fissure Completion for Lung Volume Reduction in Emphysema
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Beth Israel Deaconess Medical Center
Lead Sponsor
Pulmonx Corporation
Collaborating Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | Interventional fissure completion plus valve | Medical management only |
|---|---|---|
| What it is | A combined surgical completion of interlobar fissure (by robotic or video‑assisted thoracic surgery) followed by placement of endobronchial valves | Optimized medical management without undergoing fissure completion surgery or valve placement |
| Role in the trial | Investigational procedural treatment being evaluated | Control condition representing standard non‑interventional care |
| Primary use | To reduce lung hyperinflation and assess feasibility of delivering fissure completion plus valve placement in severe emphysema | To manage symptoms with standard non‑invasive therapies such as inhaled medications and rehabilitation |
| How it is performed | Surgical completion of interlobar fissure using stapler via robotic or VATS approach, followed by bronchoscopic placement of endobronchial valves | Continued optimized medical therapy without any surgical or procedural intervention |
| Evidence status | Under investigation; safety and feasibility being assessed in this trial | Supported by clinical guidelines as standard management to reduce symptoms and exacerbations |
| Important limitations | Requires surgical expertise, specialized centers, and unknown long‑term outcomes | May not sufficiently address hyperinflation in severe emphysema when symptoms persist despite optimal medical therapy |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Procedure day with possible deferral of valve placement within 48 hours
Participants undergo surgery to complete the lobar fissure using robotic or video-assisted thoracic surgery followed by placement of endobronchial valves during the same or closely timed procedure under general anesthesia.
1 procedure visit (in-person)
Duration - 3 months
Participants are followed up with standard care visits after endobronchial valve placement including assessments of lung function, quality of life questionnaires, dyspnea scales, CT scans, and other clinical evaluations.
Visits at 14 days and 3 months post-procedure (in-person)
Duration - 3 months
Participants in the medical management group receive maximal medical therapy and are monitored with pulmonary function testing and quality of life assessments before offering crossover to the surgical intervention.
Routine medical visits during therapy period
Duration - Procedure day plus 3 months follow-up
Participants initially assigned to medical management who choose to crossover undergo the same surgical procedure and follow-up schedule as the intervention group.
1 procedure visit and follow-up visits at 14 days and 3 months (in-person)
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
CROSSOVER
Primary Purpose
TREATMENT
Number of Arms
3
Have more questions? Get in touch with our team for quick support
Dirk-Jan Slebos, Pallav L Shah, Felix J F Herth...
https://pubmed.ncbi.nlm.nih.gov/27992862/S D Sullivan, S D Ramsey, T A Lee
https://pubmed.ncbi.nlm.nih.gov/10673466/Pallav L Shah, Felix J F Herth
https://pubmed.ncbi.nlm.nih.gov/24008689/François Maltais
https://pubmed.ncbi.nlm.nih.gov/23445862/Kenneth D Kochanek, Sherry Murphy, Jiaquan Xu...
https://pubmed.ncbi.nlm.nih.gov/29319473/Malcolm M DeCamp, Robert J McKenna, Claude C Deschamps...
https://pubmed.ncbi.nlm.nih.gov/18453353/Bartolomé R Celli, Jadwiga A Wedzicha
https://pubmed.ncbi.nlm.nih.gov/31553837/Theodoor David Koster, Dirk-Jan Slebos
https://pubmed.ncbi.nlm.nih.gov/27110109/François Maltais, Marc Decramer, Richard Casaburi...
https://pubmed.ncbi.nlm.nih.gov/24787074/Ralf Eberhardt, Daniela Gompelmann, Maren Schuhmann...
https://pubmed.ncbi.nlm.nih.gov/22459779/Beth Israel Deaconess Medical Center
Lead Sponsor
Pulmonx Corporation
Collaborating Sponsor